NCT07277842 2025-12-11
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
Sun Yat-sen University
Phase 3 Not yet recruiting
Clinical Trials
13 trialsNCT06507371 2025-06-26
mRCAT-III
Sir Run Run Shaw Hospital
Phase 3 Recruiting
NCT06794086 2025-05-13
SPARKLE-L
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Recruiting
NCT06900218 2025-04-02
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06647563 2024-10-18
Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 3 Not yet recruiting
NCT04557020 2024-05-01
Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC
Jiangxi Provincial Cancer Hospital
Phase 3 Unknown
NCT05429684 2022-06-23
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase 3 Unknown
NCT05342792 2022-04-25
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT04084626 2022-01-05
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
Beijing Friendship Hospital
Phase 3 Unknown
NCT04778956 2021-03-04
Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Recruiting
NCT04711434 2021-01-20
PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients
Sun Yat-sen University
Phase 3 Unknown
NCT03744247 2019-05-02
Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC
Sun Yat-sen University
Phase 3 Withdrawn
NCT03791918 2019-05-02
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
Sun Yat-sen University
Phase 3 Withdrawn